GeoVax Labs’ (GOVX) Buy Rating Reiterated at HC Wainwright

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $8.00 price target on the stock.

Several other equities research analysts also recently weighed in on the company. D. Boral Capital reissued a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a report on Thursday, April 10th. Alliance Global Partners cut their price target on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research note on Tuesday. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, GeoVax Labs currently has an average rating of “Buy” and an average price target of $12.90.

GeoVax Labs Stock Up 4.9 %

GOVX traded up $0.04 during midday trading on Wednesday, hitting $0.89. 327,068 shares of the company were exchanged, compared to its average volume of 601,264. The firm has a market capitalization of $12.35 million, a P/E ratio of -0.16 and a beta of 3.70. GeoVax Labs has a 1-year low of $0.73 and a 1-year high of $11.18. The firm’s 50 day moving average price is $1.40 and its 200-day moving average price is $1.97.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.49. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $2.38 million. On average, sell-side analysts predict that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its position in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares in the last quarter. Citadel Advisors LLC purchased a new position in GeoVax Labs during the 4th quarter valued at about $104,000. Virtu Financial LLC bought a new stake in GeoVax Labs in the 3rd quarter worth about $97,000. Finally, Northern Trust Corp purchased a new position in shares of GeoVax Labs during the 4th quarter worth $29,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.